MEDICATION WEIGHT LOSS Experience Real Results with Medical Weight Loss Programs
Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
After a year of weight loss injections with the GLP-1 medication Tirzepatide, he not only lost 30 pounds but also experienced dramatic improvement in hair density
doi: 10.3389/fgene.2016.00095